Antihypertensive drugs and the heart

被引：3

作者：

Diamond J.A. ^{[1
]}

Phillips R.A. ^{[1
]}

机构：

[1] Department of Nuclear Cardiology, Long Island Jewish Medical Center, New Hyde Park, NY 10040

来源：

Current Cardiology Reports | 2004年 / 6卷 / 6期

关键词：

Left Ventricular Hypertrophy; Diastolic Dysfunction; Cardiac Hypertrophy; Left Ventricular Mass; Candesartan;

D O I：

10.1007/s11886-004-0047-2

中图分类号：

学科分类号：

摘要：

Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are early signs of cardiac end-organ damage (hypertensive heart disease) in patients with arterial hypertension. The presence of LVH or CHF-D confers increased risk of cardiovascular morbidity and mortality in patients with hypertension. Regression of left ventricular mass with antihypertensive therapy is associated with reduction in cardiovascular events. Antihypertensive therapy should be geared to both lower blood pressure and specifically reverse the pathophysiologic processes that may be independent of actual blood pressure. This review summarizes current and emerging approaches to the treatment of individuals with hypertensive heart disease. Copyright © 2004 by Current Science Inc.

引用

页码：409 / 415

页数：6

共 57 条

[1]

Levy D., Anderson K.M., Savage D., Et al., Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham heart study, Ann. Int. Med., 108, pp. 7-13, (1988)

[2]

Casale P.N., Devereux R.B., Milner M., Et al., Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men, Ann. Intern. Med., 105, pp. 173-178, (1986)

[3]

Levy D., Garrison R.J., Savage D.D., Et al., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study, N. Engl. J. Med., 322, pp. 1561-1566, (1990)

[4]

Bikkina M., Larson M.G., Levy D., Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy, J. Am. Coll. Cardiol., 22, pp. 1111-1116, (1993)

[5]

Klingbeil A.U., Schneider M., Martus P., Et al., A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension, Am. J. Med., 115, pp. 41-46, (2003)

[6]

Cooper R.S., Simmons B.E., Castaner A., Et al., Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed, Am. J. Cardiol., 65, pp. 441-445, (1990)

[7]

Ghali J.K., Liao Y., Simmons B., Et al., The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease, Ann. Intern. Med., 117, pp. 831-836, (1992)

[8]

Schmieder R.E., Martus P., Klingbeil A., Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies, JAMA, 275, pp. 1507-1513, (1996)

[9]

Muiesan M.L., Salvetti M., Rizzoni D., Et al., Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment, J. Hypertens., 13, pp. 1091-1095, (1995)

[10]

Bromberg J.E., Rinkel G.J., Algra A., Et al., Outcome in familial subarachnoid hemorrhage, Stroke, 26, pp. 961-963, (1995)

← 1 2 3 4 5 6 →